Cargando…
Effect of (1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients
We previously reported the results of a phase II trial of anti‐PD‐1 antibody plus anti‐vascular endothelial growth factor receptor 2 inhibitors and eribulin in heavily pretreated advanced triple‐negative breast cancer with a favorable objective response rate (ORR) of 37.0% (NCT04303741). Here we rep...
Autores principales: | Tian, Zhenluan, Rao, Qunxian, He, Zhanghai, Zhao, Wei, Chen, Liangyu, Liu, Jieqiong, Wang, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551590/ https://www.ncbi.nlm.nih.gov/pubmed/37640025 http://dx.doi.org/10.1111/cas.15937 |
Ejemplares similares
-
Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer
por: Yang, Yaping, et al.
Publicado: (2019) -
Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023) -
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022) -
Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023) -
Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)